Dr Mike Themis is the inventor of TestAVec's technology portfolio and leader of all research activities. 

 

Mike has 20 years experience, over 60 GT relevant publications and won funding awards from Innovate UK, NC3Rs, MRC, Wellcome Trust, Muscular Dystrophy Association, Ataxia U.K. and FARA U.S. and Australasia to explore gene therapy of several genetic diseases including Cystic fibrosis, Duchenne muscular dystrophy, familial hypercholesterolaemia, haemophilia B and Freidriech ataxia (FRDA)..

 

He has developed in vitro and in vivo LV and AAV genotoxicity models and together with GeneWerk CEO Manfred Schmidt led Phase I and Phase II of the NC3R InMutaGene CRACKIT Challenge in collaboration with GSK plc and Novartis AG which resulted in the formation of the TestAVec's gene therapy safety platform.

​

Mike's ambition is that his toxicity and safety assays become gold standard for vector safety testing.

​

​